SLHM Therapeutics’ scientific founders have contributed to peer-reviewed research advancing the understanding of cancer and pediatric brain tumors, including medulloblastoma.
Dr. Michael D. Taylor is a pediatric neurosurgeon-scientist and an internationally recognized leader in pediatric brain tumor research. His work focuses on the molecular genetics, developmental origins, progression, and treatment of medulloblastoma and other childhood brain tumors.
Nature Cell Biology, 2025
This research examines how metastatic medulloblastoma changes the environment surrounding the brain and spinal cord in ways that support additional tumor growth and spread. Dr. Taylor served as the senior and corresponding author.
Nature Genetics, 2025
This study investigates how the ZIC1 gene can contribute to the development of medulloblastoma within a specific region and stage of cerebellar development. Dr. Taylor served as a senior and corresponding author.
Nature Cell Biology, 2024
This study identifies a signaling mechanism that helps aggressive Group 3 medulloblastoma cells maintain stem-cell-like properties associated with tumor growth, survival, and recurrence.
Cancer Research, 2024
This research examines how the three-dimensional organization of DNA differs among medulloblastoma subgroups and may help explain important differences in tumor biology and behavior.
Nature Cell Biology, 2025
This research examines how metastatic medulloblastoma changes the environment surrounding the brain and spinal cord in ways that support additional tumor growth and spread. Dr. Taylor served as the senior and corresponding author.
Nature Genetics, 2025
This study investigates how the ZIC1 gene can contribute to the development of medulloblastoma within a specific region and stage of cerebellar development. Dr. Taylor served as a senior and corresponding author.
Nature Cell Biology, 2024
This study identifies a signaling mechanism that helps aggressive Group 3 medulloblastoma cells maintain stem-cell-like properties associated with tumor growth, survival, and recurrence.
Cancer Research, 2024
This research examines how the three-dimensional organization of DNA differs among medulloblastoma subgroups and may help explain important differences in tumor biology and behavior.
Dr. Anindya Bagchi is a cancer geneticist whose research examines the genetic and molecular mechanisms that contribute to cancer development and progression. His work includes the study of genomic alterations, gene regulation, cancer dependencies, and potential therapeutic vulnerabilities.
Developmental Cell, 2025
This study identifies potassium-channel dependencies that appear to play an important role in maintaining sonic hedgehog, or SHH, medulloblastoma. The findings highlight biological vulnerabilities that may inform the development of future therapeutic strategies. Dr. Bagchi contributed to the research as a coauthor.
The publications and external profiles referenced on this page represent academic research conducted by the individual investigators and their collaborators. They are provided for scientific background and do not necessarily describe research sponsored by SLHM Therapeutics or the company’s current programs, product candidates, intellectual property, or proprietary technology.